UNSPSC 51141567: Milacemide

This classification denotes an anticonvulsant agent with the molecular formula C7H16N2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0HXT24RECU, chemically known as acetamide, 2-(pentylamino)- but generally known as milacemide, which bears US NIH Compound Identifier 53569. European Medicines Agency schedules Milacemide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08960MIG.

UNSPSC 51141567 Milacemide is a Commodity code that nominally identifies a specific pharmaceutical agent, but recent state and local solicitations show activity misaligned with the code's narrow scope. The three most recent opportunities tagged to this code address broader pharmaceutical procurement: Seminole County, Florida is procuring naloxone and drug deactivation systems through an IFB; the Texas Health and Human Services Commission issued an RFI exploring direct-to-manufacturer prescription programs; and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) is soliciting manufacturers of generic multi-source pharmaceuticals and over-the-counter products through an RFP. State and local issuing bodies using this code span county health departments, state health and human services agencies, and multistate cooperative purchasing alliances. The actual scope of work diverges significantly from the code name—the recent opportunities reflect systemwide pharmaceutical procurement covering naloxone supply chains, OTC products, generic pharmaceuticals distributed through authorized wholesalers, and direct-to-manufacturer contracting models rather than procurement of milacemide specifically.

Activity spans Florida, Texas, and Minnesota with a multistate cooperative vehicle (MMCAP) extending to Oregon. The Seminole County IFB (IFB60459723LAS, due July 26, 2023) seeks 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries and a two-year initial term plus one-year renewal option. The Texas HHS RFI (HHS0017013, response due April 3, 2026) gathers vendor capabilities for direct-to-manufacturer prescription contracting outside traditional pharmacy benefit manager and wholesaler channels. The MMCAP RFP (S1070000015802, proposals due March 26, 2026) establishes multi-award contracts for generic pharmaceuticals and OTC products with products available through three authorized wholesalers—AmerisourceBergen (Cencora), Cardinal Health, and Morris & Dickson—effective July 1, 2026, evaluated primarily on price competitiveness (75 percent weight) alongside fixed pricing, administrative fee compliance, and EDI capability. This code shows limited semantic alignment with the opportunities posted under it and warrants verification against actual purchasing intent before pursuit.